As such, CD5KO FHVH3/VH1 CAR-T cells showed prolonged and sustained efficacy against CD5+ T-ALL cell lines, such as Jurkat, CCRF-CEM, MOLT4, SupT1 in vitro, and CCRF-CEM in vivo, with moderate cytokine production, proved that this new CD5 CAR deserved more exploration (66). This evidence concerns the gene CD5 and acute lymphoblastic leukemia.